Small molecules modulator of epigenetic regulation and their therapeutic applications
Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.
1. A method of selectively modulating a myocyte enhancer factor-2 (MEF2) and its functions, said method comprising:
contacting the MEF2 with a small molecule interfacial inhibitor,
wherein said interfacial inhibitor is a compound having a formula of
and
whereby said interfacial inhibitor modulates the MEF2's function by disrupting the interactions between the MEF2 and a functional binding partner at the MEF2 binding site.
2. The method of claim 1 , wherein said MEF2 is MEF2A.
3. The method of claim 1 , wherein said MEF2 is MEF2B.
4. The method of claim 1 , wherein said MEF2 is MEF2C.
5. The method of claim 1 , wherein said MEF2 is MEF2D.
6. A method of modulating myocyte enhancer factor-2 functions in a subject suffering from a disease related to transcription factor dysregulation, comprising:
administering an interfacial inhibitor to said subject,
wherein said transcription factor dysregulation is a dysregulation of a transcription factor selected from a group consisting of MEF2A, MEF2B, MEF2C, and MEF2D, or combinations thereof, and,
wherein said interfacial inhibitor is a compound having a formula of
7. The method of claim 6 , wherein said transcription factor dysregulation is a dysregulation of MEF2A.
8. The method of claim 6 , wherein said transcription factor dysregulation is a dysregulation of MEF2B.
9. The method of claim 6 , wherein said disease is one selected from transplant rejection, inflammation, autoimmune diseases, neurodegenerative diseases, cancer, and cardiovascular disease.
10. The method of claim 6 , wherein said transcription factor dysregulation is a dysregulation of MEF2C.
11. The method of claim 6 , wherein said transcription factor dysregulation is a dysregulation of MEF2D.